Skip to the main content.

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals, "Cellicon Valley" and the "Golden Triangle

In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.

Click here to gain an understanding of why investors believe significant returns will be made from these technologies.

CAR-T cell therapy for cancer: The patient's in the process

CAR-T cell therapy for cancer: The patient's in the process

Around 1,000 people are diagnosed with cancer every day in the UK. Fortunately, outcomes continue to improve, with around half of those diagnosed...

Read More
Engineering Challenges in Designing Pharmaceutical Isolators

Engineering Challenges in Designing Pharmaceutical Isolators

In this latest blog, James Lau, one of 3P’s Project Engineers, tells us all about barrier systems across a range of areas. Specifically taking a...

Read More
Don't let your filling equipment dictate your drug formulation.

Don't let your filling equipment dictate your drug formulation.

In early-stage pharmaceutical development, poor powder flow is rarely the root issue, it’s simply a symptom. The real challenge for formulation...

Read More